In 2014, the FDA approved the first point-of-care device (NephroCheck test) that allows the determination of both urinary IGFBP-7 and TIMP-2 in critically ill patients with an increased risk of developing moderate-to-severe AKI. Here, TIMP2 is linked to acute kidney injury.